Due to the complicated pathogenesis of Alzheimer's disease (AD), the development of multitargeted agents to simultaneously interfere with multiple pathological processes of AD is a potential choice. Glycogen synthase kinase-3β (GSK-3β) plays a vital role in the AD pathological process. In this study, we discovered a novel 1H-pyrrolo[2,3-b]pyridine derivative B10 as a GSK-3β inhibitor that features with a quinolin-8-ol moiety to target the metal dyshomeostasis of AD. B10 potently inhibited GSK-3β with an IC 50 of 66 ± 2.5 nM. At the concentration of 20 µM, B10 increased β-catenin abundance (β-catenin/GAPDH: 0.83 ± 0.086 vs. 0.30 ± 0.016), phosphorylated GSK-3β at Ser9 (p-GSK-3β/GAPDH: 0.53 ± 0.045 vs. 0.35 ± 0.012), and decreased the phosphorylated tau level (p-tau/GAPDH: 0.33 ± 0.065 vs. 0.83 ± 0.061) in SH-SY5Y cells. Unlike other GSK-3β inhibitors, B10 had a direct effect on Aβ by inhibiting Aβ 1-42 aggregation and promoting the Aβ 1-42 aggregate disassociation. It selectively chelated with Cu 2+ , Zn 2+ , Fe 3+, and Al 3+ , and targeted AD metal dyshomeostasis. Moreover, B10 effectively increased the mRNA expression of the recognized neurogenesis markers, GAP43, N-myc, and MAP-2, and promoted the differentiated neuronal neurite outgrowth, possibly through the GSK-3β and β-catenin signal pathways. Therefore, B10 is a potent and unique GSK-3β inhibitor that has a direct on Aβ and serves as a multifunctional anti-AD agent for further investigations.Cells 2020, 9, 649 2 of 15 Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase largely expressed in the central nervous system (CNS), plays important roles in metabolism, proliferation, and apoptosis [24]. The two subtypes, GSK-3α (51 kDa) and GSK-3β (47 kDa), are 98% identical in their respective catalytic domains [25]. GSK-3β is predominantly the main isoform in most brain areas and the key kinase in AD responsible for the abnormal hyperphosphorylation of the microtubule-associated tau protein [26][27][28]. The hyperphosphorylated tau impairs the interaction between tau proteins and microtubules, leading to the detachment of tau from microtubules, destabilizing the microtubules in the neurons. The accumulation of hyperphosphorylated tau further generates paired helical filaments and subsequent aggregates to form the intracellular NFTs, one important biomarker of AD [29][30][31]. Moreover, increased GSK-3β activity may induce Aβ formation through its regulation of γ-secretase in the cleavage of the amyloid-precursor protein (APP) [32]. Overactivation of GSK-3β is also involved in neuroinflammation, neuronal death, and apoptosis through cell signal pathways [33,34]. Both in AD model and preclinical and clinical studies, GSK-3β has been proven as a therapeutic target for AD [35][36][37][38].In an effort to find potent GSK-3β inhibitors to target multifacets of AD [39], we report here a unique and potent GSK-3β inhibitor, 6-(5-(4-((pyridin-4-ylamino)methyl)phenyl)-1H-pyrrolo[2,3-b] pyridin-3-yl)quinolin-8-ol (B10), which has a direct effect on Aβ targets tau an...